secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2026-05-28T20:01:40+00:00
Accession:  0001193125-26-245163
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma enters new $1.8B unsecured revolver maturing 2031
----------------------------------------------------------------

- New $1.8B unsecured revolving credit facility replaces existing agreement from 2021.
- Matures May 22, 2031; interest rate based on SOFR or base rate plus margin per pricing grid.
- Covenants: leverage ratio ≤4.00x (4.50x post-acquisition), portfolio cash flow ≤5.00x (5.50x), coverage ≥2.50x.
- Borrower: Royalty Pharma Holdings Ltd; guarantors: Royalty Pharma plc and Royalty Pharma Manager, LLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312526245163/0001193125-26-245163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312526245163/d131735d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-245163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer